You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

B-cell Maturation Antigen

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma, Plasma Cell Tumor, Malignant Plasma Cell Tumor Trial in Houston (Radiation Therapy)

Recruiting
  • Multiple Myeloma
  • +2 more
  • Radiation Therapy
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2022

Multiple Myeloma Trial in Nashville (Cevostamab, Tocilizumab)

Recruiting
  • Multiple Myeloma
  • Nashville, Tennessee
    Tennessee Onc., PLLC - SCRI
Sep 8, 2022

Relapsed/ Refractory Multiple Myeloma Trial (GC012F)

Not yet recruiting
  • Relapsed/ Refractory Multiple Myeloma
  • GC012F
  • (no location specified)
Apr 28, 2023

Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,

Not yet recruiting
  • Kidney Transplant
  • +2 more
  • Boston, Massachusetts
  • +2 more
Sep 20, 2023

Multiple Myeloma, Relapse Multiple Myeloma, Refractory Multiple Myeloma Trial in Shenzhen (BCMA CAR-T cells)

Recruiting
  • Multiple Myeloma
  • +2 more
  • BCMA CAR-T cells
  • Shenzhen, Guangdong, China
    Li Yu
Dec 7, 2021

Refractory Multiple Myeloma, Relapse Multiple Myeloma Trial in Milwaukee (Belantamab mafodotin)

Recruiting
  • Refractory Multiple Myeloma
  • Relapse Multiple Myeloma
  • Belantamab mafodotin
  • Milwaukee, Wisconsin
    Froedtert & the Medical College of Wisconsin
Aug 3, 2022

Multiple Myeloma Trial in New York (Ide-cel (bb2121))

Recruiting
  • Multiple Myeloma
  • Ide-cel (bb2121)
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 6, 2022

Relapsed/Refractory Multiple Myeloma, Amyloid Light-chain Amyloidosis Trial (SAR445514)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Amyloid Light-chain Amyloidosis
  • (no location specified)
Apr 20, 2023

Multiple Myeloma Trial in Chicago, Boston, Milwaukee (PHE885)

Recruiting
  • Multiple Myeloma
  • PHE885
  • Chicago, Illinois
  • +4 more
Jul 28, 2022

Multiple Myeloma Trial in New York (EGFRt/BCMA-41BBz CAR T cell, Cyclophosphamide, Lenalidomide.)

Active, not recruiting
  • Multiple Myeloma
  • EGFRt/BCMA-41BBz CAR T cell
  • +2 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Mar 7, 2022

Multiple Myeloma Trial in Shanghai (Anti-BCMA CAR-T cells, Fludarabine, Cyclophosphamide)

Recruiting
  • Multiple Myeloma
  • Anti-BCMA CAR-T cells
  • +3 more
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Aug 29, 2021

Multiple Myeloma Trial in Bethesda, Oklahoma City, Fairfax (Descartes-08, Fludarabine, Cyclophosphamide)

Completed
  • Multiple Myeloma
  • Descartes-08
  • +2 more
  • Bethesda, Maryland
  • +2 more
Mar 10, 2022

Myasthenia Gravis, Generalized Trial in United States (Descartes-08)

Recruiting
  • Myasthenia Gravis, Generalized
  • Carlsbad, California
  • +8 more
Jan 27, 2023

Multiple Myeloma Trial in Worldwide (PHE885)

Recruiting
  • Multiple Myeloma
  • PHE885
  • VIC, Melbourne, Australia
  • +4 more
Jul 20, 2022

Relapsed or Refractory Multiple Myeloma Trial in Nagoya, Shibuya-ku (Elranatamab (PF-06863135))

Active, not recruiting
  • Relapsed or Refractory Multiple Myeloma
  • Elranatamab (PF-06863135)
  • Nagoya, Aichi, Japan
  • +1 more
Jun 20, 2022

Multiple Myeloma Trial in China (LCAR-B38M CAR-T Cell)

Recruiting
  • Multiple Myeloma
  • LCAR-B38M CAR-T Cell
  • Beijing, Beijing, China
  • +7 more
Dec 30, 2021

Multiple Myeloma Trial in Charlotte (Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin)

Recruiting
  • Multiple Myeloma
  • Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
  • Charlotte, North Carolina
    Levine Cancer Institute
Nov 17, 2021

Multiple Myeloma Trial in Japan, United States (JNJ-68284528)

Completed
  • Multiple Myeloma
  • JNJ-68284528
  • Phoenix, Arizona
  • +20 more
Oct 5, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)

Completed
Has Results
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 3, 2022

Multiple Myeloma Trial in Suzhou (clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells)

Recruiting
  • Multiple Myeloma
  • clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Oct 22, 2021

Multiple Myeloma Trial in Sanhe (BCMA/CD19 dual-target CAR-T cell immunotherapy)

Not yet recruiting
  • Multiple Myeloma
  • BCMA/CD19 dual-target CAR-T cell immunotherapy
  • Sanhe, Hebei, China
    Hebei Yanda Ludaopei Hospital
Jun 1, 2020

Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell

Not yet recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • +5 more
  • Boston, Massachusetts
  • +1 more
Jun 28, 2023

19 and 22+ B Cell Hematologic Tumors Trial in Wuhan (Autologous CD19/CD22 Chimeric Antigen Receptor T-cells)

Recruiting
  • 19 and 22+ B Cell Hematologic Tumors
  • 19 and 20+ B Cell Hematologic Tumors
  • Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
  • Wuhan, Hubei, China
    Tongji Hospital
Jan 11, 2023

Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in San Francisco (Manufactured Anti-BCMA CAR-T cells, Fludarabine,

Recruiting
  • Refractory Multiple Myeloma
  • Relapsed Multiple Myeloma
  • Manufactured Anti-BCMA CAR-T cells
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Jan 6, 2023

Multiple Myeloma Trial in Worldwide (JNJ-68284528, Pomalidomide, Bortezomib)

Active, not recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +87 more
Jan 17, 2023